<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899079</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-00163</org_study_id>
    <nct_id>NCT01899079</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay</brief_title>
  <official_title>Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoString Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cedar Associates LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Espanol de Investigacion del Cancer de Mama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NanoString Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the extent to which the Prosigna™ Breast&#xD;
      Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment&#xD;
      recommendations regarding adjuvant chemotherapy and actual treatments received for patients&#xD;
      with early-stage breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Changes in treatment recommendations will include (1) hormonal therapy alone, (2) hormonal&#xD;
      therapy plus chemotherapy, and (3) changes in types of chemotherapy if chemotherapy was&#xD;
      recommended before and after the Prosigna test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">217</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE breast tumor tissue samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative&#xD;
        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women&#xD;
        who meet the entry criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage&#xD;
             invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0)&#xD;
&#xD;
               1. Estrogen receptor status will be evaluated by Immunohistochemistry (IHC)and more&#xD;
                  than 1% of stained tumor cells will be considered positive.&#xD;
&#xD;
               2. HER2 status will be evaluated by (IHC; 0 or 1+, or 2+ will be considered&#xD;
                  negative) and by in-situ fluorescence hybridization.&#xD;
&#xD;
          -  Postmenopausal females, which is defined as:&#xD;
&#xD;
               1. Natural Amenorrhea &gt; 12 months, regardless of age&#xD;
&#xD;
               2. Bilateral oophorectomy, regardless of age (the oophorectomy must have been&#xD;
                  carried out at least 4 weeks before entering the study)&#xD;
&#xD;
               3. Radiological castration with amenorrhea &gt; 3 months, regardless of age&#xD;
&#xD;
               4. Hysterectomy and postmenopausal blood levels&#xD;
&#xD;
          -  Able to give consent&#xD;
&#xD;
          -  Eligible for treatment of breast cancer with adjuvant chemotherapy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor size T3-T4&#xD;
&#xD;
          -  Non-invasive breast cancer (e.g., Paget's disease, DCIS)&#xD;
&#xD;
          -  Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+)&#xD;
&#xD;
          -  Tumors that are estrogen-receptor negative or HER2 positive&#xD;
&#xD;
          -  Have metastatic disease&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Unable to complete patient reported outcome surveys&#xD;
&#xD;
          -  Have contraindications for adjuvant chemotherapy&#xD;
&#xD;
               -  Age, performance status, significant comorbidities&#xD;
&#xD;
          -  ECOG performance status &gt; 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Martin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital G.U. Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Prosigna</keyword>
  <keyword>FFPE</keyword>
  <keyword>node negative</keyword>
  <keyword>estrogen receptor positive</keyword>
  <keyword>HER2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

